ABVC BioPharma reports Q2 2025 results with 103% asset growth and $350K licensing revenue

ABVC BIOPHARMA, INC.

2025-Q2 EPS reported -$0.19

Total consolidated assets increased 103% to $16.2 million from $8.0 million in Q2 2024
Shareholders' equity rose to $9.5 million from $8.0 million year-over-year
Diluted loss per share improved to $(0.13) from $(0.42) full-year 2024 loss
Acquired farmland in Taiwan valued at approximately $3.3 million for R&D and GMP expansion
Received $350,000 in licensing revenue from AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation in July 2025

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.